Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).
Emons G, Gorchev G, Harter P, Wimberger P, Stähle A, Hanker L, Hilpert F, Beckmann MW, Dall P, Gründker C, Sindermann H, Sehouli J. Emons G, et al. Among authors: gorchev g. Int J Gynecol Cancer. 2014 Feb;24(2):260-5. doi: 10.1097/IGC.0000000000000044. Int J Gynecol Cancer. 2014. PMID: 24418927 Free PMC article. Clinical Trial.
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.
Emons G, Kaufmann M, Gorchev G, Tsekova V, Gründker C, Günthert AR, Hanker LC, Velikova M, Sindermann H, Engel J, Schally AV. Emons G, et al. Among authors: gorchev g. Gynecol Oncol. 2010 Dec;119(3):457-61. doi: 10.1016/j.ygyno.2010.08.003. Epub 2010 Sep 9. Gynecol Oncol. 2010. PMID: 20828803 Clinical Trial.
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P. Emons G, et al. Among authors: gorchev g. Gynecol Oncol. 2014 Jun;133(3):427-32. doi: 10.1016/j.ygyno.2014.03.576. Epub 2014 Apr 5. Gynecol Oncol. 2014. PMID: 24713545 Clinical Trial.
[Prognostic models in ovarian cancer].
Tomov S, Gorchev G, Tsingilev D, Khinkova N. Tomov S, et al. Among authors: gorchev g. Akush Ginekol (Sofiia). 2007;46(5):22-7. Akush Ginekol (Sofiia). 2007. PMID: 17974178 Bulgarian. No abstract available.
134 results